Inflammatory markers and bariatric surgery: A meta-analysis

Inflammation Research

Volumn 61, Issue 8, 2012, Pages 789-807

  Rao, S Raghavendra ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bariatric surgery; CRP; IL 6; TNF

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

BARIATRIC SURGERY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FOLLOW UP; HUMAN; INFLAMMATION; MORBID OBESITY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SURGICAL PATIENT; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW;

ANIMALS; BARIATRIC SURGERY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; INTERLEUKIN-6; OBESITY, MORBID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865114872     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0473-3     Document Type: Review

References (119)

1. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008-12. (Pubitemid 30214957)
2. Pardina E, Ferrer R, Baena-Fustegueras JA, Rivero J, Lecube A, Fort JM, Vargas V, Catalan R, Peinado-Onsurbe J. Only C-reactive protein, but not TNF-alpha or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg. 2012;22:131-9.
3. Huang H, Kasumov T, Gatmaitan P, Heneghan HM, Kashyap SR, Schauer PR, Brethauer SA, Kirwan JP. Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients. Obesity (Silver Spring). 2011;19:2235-40.
4. Komorowski J, Jankiewicz-Wika J, Kolomecki K, Cywinski J, Piestrzeniewicz K, Swietoslawski J, Stepien H. Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine. 2011;55:56-61.
5. Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis. 2011;7:618-24.
6. Pallayova M, Steele KE, Magnuson TH, Schweitzer MA, Smith PL, Patil SP, Bevans-Fonti S, Polotsky VY, Schwartz AR. Sleep apnea determines soluble TNF-alpha receptor 2 response to massive weight loss. Obes Surg. 2011;21:1413-23.
7. de Luis DA, Pacheco D, Aller R. Influence of G308A polymorphism of tumor necrosis factor alpha gene on surgical results of biliopancreatic diversion. Obes Surg. 2010;20:221-5.
8. Tussing-Humphreys L, Pini M, Ponemone V, Braunschweig C, Fantuzzi G. Suppressed cytokine production in whole blood cultures may be related to iron status and hepcidin and is partially corrected following weight reduction in morbidly obese pre-menopausal women. Cytokine. 2011;53:201-6.
9. Kopp HP, Krzyzanowska K, Schernthaner GH, Kriwanek S, Schernthaner G. Relationship of androgens to insulin resistance and chronic inflammation in morbidly obese premenopausal women: studies before and after vertical banded gastroplasty. Obes Surg. 2006;16:1214-20. (Pubitemid 44433160)
10. Bueter M, Dubb SS, Gill A, Joannou L, Ahmed A, Frankel AH, Tam FW, le Roux CW. Renal cytokines improve early after bariatric surgery. Br J Surg. 2010;97:1838-44.
11. Vazquez LA, Pazos F, Berrazueta JR, Fernandez-Escalante C, Garcia-Unzueta MT, Freijanes J, Amado JA. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316-22. (Pubitemid 40116674)
12. Tussing-Humphreys LM, Nemeth E, Fantuzzi G, Freels S, Holterman AX, Galvani C, Ayloo S, Vitello J, Braunschweig C. Decreased serum hepcidin and improved functional iron status 6 months after restrictive bariatric surgery. Obesity (Silver Spring). 2010;18:2010-6.
13. Maruna P, Gurlich R, Fried M, Frasko R, Chachkhiani I, Haluzik M. Leptin as an acute phase reactant after non-adjustable laparoscopic gastric banding. Obes Surg. 2001;11:609-14. (Pubitemid 32907131)
14. Tschoner A, Sturm W, Ress C, Engl J, Kaser S, Laimer M, Laimer E, Klaus A, Tilg H, Patsch JR, Ebenbichler CF. Effect of weight loss on serum pigment epithelium-derived factor levels. Eur J Clin Invest. 2011;41:937-42.
15. Sainsbury A, Goodlad RA, Perry SL, Pollard SG, Robins GG, Hull MA. Increased colorectal epithelial cell proliferation and crypt fission associated with obesity and roux-en-Y gastric bypass. Cancer Epidemiol Biomarkers Prev. 2008;17:1401-10.
16. van de Sande-Lee S, Pereira FR, Cintra DE, Fernandes PT, Cardoso AR, Garlipp CR, Chaim EA, Pareja JC, Geloneze B, Li LM, Cendes F, Velloso LA. Partial reversibility of hypothalamic dysfunction and changes in brain activity after body mass reduction in obese subjects. Diabetes. 2011;60:1699-704.
17. Ress C, Tschoner A, Engl J, Klaus A, Tilg H, Ebenbichler CF, Patsch JR, Kaser S. Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Invest. 2010;40:277-80.
18. Perez-Romero N, Serra A, Granada ML, Rull M, Alastrue A, Navarro-Diaz M, Romero R, Fernandez-Llamazares J. Effects of two variants of Roux-en-Y Gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up. Obes Surg. 2010;20:600-9.
19. Hakeam HA, O'Regan PJ, Salem AM, Bamehriz FY, Eldali AM. Impact of laparoscopic sleeve gastrectomy on iron indices: 1 year follow-up. Obes Surg. 2009a;19:1491-6.
20. Agrawal V, Krause KR, Chengelis DL, Zalesin KC, Rocher LL, McCullough PA. Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis. 2009;5:20-6.
21. Hakeam HA, O'Regan PJ, Salem AM, Bamehriz FY, Jomaa LF. Inhibition of C-reactive protein in morbidly obese patients after laparoscopic sleeve gastrectomy. Obes Surg. 2009b;19:456-60.
22. Manco M, Fernandez-Real JM, Equitani F, Vendrell J. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab. 2007;92:483-90.
23. Chen SB, Lee YC, Ser KH, Chen JC, Chen SC, Hsieh HF, Lee WJ. Serum C-reactive protein and white blood cell count in morbidly obese surgical patients. Obes Surg. 2009;19:461-6.
24. Gannage-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, Trak-Smayra V. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008;158:353-9. (Pubitemid 351405000)
25. Lin E, Phillips LS, Ziegler TR, Schmotzer B, Wu K, Gu LH, Khaitan L, Lynch SA, Torres WE, Smith CD, Gletsu-Miller N. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes. 2007a;56:735-42. (Pubitemid 46348478)
26. Lin LY, Lee WJ, Shen HN, Yang WS, Pai NH, Su TC, Liau CS. Nitric oxide production is paradoxically decreased after weight reduction surgery in morbid obesity patients. Atherosclerosis. 2007b;190:436-42.
27. Geloneze SR, Geloneze B, Morari J, Matos-Souza JR, Lima MM, Chaim EA, Pareja JC, Velloso LA. PGC1alpha gene Gly482Ser polymorphism predicts improved metabolic, inflammatory and vascular outcomes following bariatric surgery. Int J Obes (Lond). 2012;36:363-8.
28. De Ciuceis C, Porteri E, La Boria E, Boari G, Mittempergher F, Di Betta E, Casella C. Subcutaneous small resistance artery morphology and circulating indices of inflammation/oxidative stress in obese patients before and after bariatric surgery and consistent weight loss. High Blood Press Cardiovasc Prev. 2011;18:158.
29. Melendez Araujo M, De Matos Arruda S, Silva Oliveira M, Franca F, Barros R, Medeiros Santos R, Cubas Rolim E, Daher Milhomem P, Ferreira Neves C. Evaluation of inflamatory and metabolic state of patients with steatosis before Roux-en-Y gastric bypass procedure and after six months of operation. Obes Surg. 2011;21:1129.
30. Di Renzo L, Carbonelli MG, Bianchi A, Iacopino L, Fiorito R, Di Daniele N, De Lorenzo A. Body composition changes after laparoscopic adjustable gastric banding: what is the role of - 174GC interleukin-6 promoter gene polymorphism in the therapeutic strategy? Int J Obes (Lond). 2012;36:369-78.
31. Wolf T, Rauschmayer M, Dressler M, Ring A, Britz A, Lohmann T. Changes of hormone levels in the early period after bariatric surgery. Obes Surg. 2011;21:1079.
32. Fica S, Sirbu A, Copaescu C, Olaru R, Florea S. Significant improvement in metabolic status 6 months after bariatric surgery. Diabetes Technol Ther. 2011;13:223-4.
33. Wong A, Chan D, Armstrong J, Watts G. Effect of laparoscopic sleeve gastrectomy on elevated C-reactive protein and atherogenic dyslipidemia in morbidly obese patients. Clin Biochem. 2011;44:342-4.
34. Faria G, Preto J, Gouveia A, Barbosa J, Carneiro S, Costa E, Teixeira C, Gil C, Sousa-Rodrigues J, Alves J. Decrease in inflammatory state and insulin-resistance 6 to 12 months after laparoscopic Roux-en-Y gastric bypass (LRYGB). Obes Surg. 2010;20:1056.
35. Komorowski J, Jankiewicz-Wika J, Kolomecki K, Cywinski J, Piestrzeniewicz K. Peripheral blood concentrations of adipocytokines, inflammation and metabolic syndrome markers after bariatric surgery. Obes Rev. 2010;11:251.
36. Boesing F, Moreira E, Wilhelm-Filho D, Vigil S, Parizottto E, Inacio D, Portari G, Trindade E, Jordao-Junior A, Frode T. Roux-en-Y bypass gastroplasty: markers of oxidative stress 6 months after surgery. Obes Surg. 2010;20:1236-44.
37. Richette P, Poitou C, Garnero P, Vicaut E, Bouillot JL, Lacorte JM, Basdevant A, Clement K, Bardin T, Chevalier X. Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis. 2011;70:139-44.
38. Lima MM, Pareja JC, Alegre SM, Geloneze SR, Kahn SE, Astiarraga BD, Chaim EA, Geloneze B. Acute effect of roux-en-y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3871-5.
39. Woodard G, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton J. One year improvements in cardiovascular risk factors: A comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg. 2010;20: 578-82.
40. Swarbrick MM, Stanhope KL, Austrheim-Smith IT, Van Loan MD, Ali MR, Wolfe BM, Havel PJ. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia. 2008;51:1901-11.
41. Malheiros C, Freitas W, Saleh M, Taha M, Bertolami M. Bariatric surgery decreases the inflammatory response in the 6 months post-operatory. Obes Surg. 2009;19:1013.
42. Carroll J, Franks S, Smith A, Phelps D. Visceral adipose tissue loss and insulin resistance 6 months after laparoscopic gastric banding surgery: A preliminary study. Obes Surg. 2009;19: 47-55.
43. Chacon MR, Miranda M, Jensen CH, Fernandez-Real JM, Vilarrasa N, Gutierrez C, Naf S, Gomez JM, Vendrell J. Human serum levels of fetal antigen 1 (FA1/Dlk1) increase with obesity, are negatively associated with insulin sensitivity and modulate inflammation in vitro. Int J Obes (Lond). 2008;32:1122-9. (Pubitemid 351986196)
44. Zagorski S, Papa N, Chung M. The effect of weight loss after gastric bypass on C-reactive protein levels. Surg Obes Relat Dis. 2005;1:81-5.
45. Broch M, Gomez JM, Auguet MT, Vilarrasa N, Pastor R, Elio I, Olona M, Garcia-Espana A, Richart C. Association of retinolbinding protein-4 (RBP4) with lipid parameters in obese women. Obes Surg. 2010;20:1258-64.
46. Schaller G, Aso Y, Schernthaner GH, Kopp HP, Inukai T, Kriwanek S, Schernthaner G. Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes Surg. 2009;19:351-6.
47. Botella-Carretero JI, Alvarez-Blasco F, Martinez-Garcia MA, Luque-Ramirez M. The decrease in serum IL-18 levels after bariatric surgery in morbidly obese women is a time-dependent event. Obes Surg. 2007;17:1199-208. (Pubitemid 351321326)
48. Moschen AR, Molnar C, Enrich B, Geiger S, Ebenbichler CF, Tilg H. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med. 2011;17:840-5.
49. Simon I, Escote X, Vilarrasa N, Gomez J, Fernandez-Real JM, Megia A, Gutierrez C, Gallart L, Masdevall C, Vendrell J. Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women. Obesity (Silver Spring). 2009;17:1124-8.
50. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediat Inflamm. 2010;2010:513948.
51. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196-200. (Pubitemid 27525539)
52. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847-50. (Pubitemid 28496456)
53. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Investig. 2006;116:3015-25. (Pubitemid 44684486)
54. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig. 2003;112: 1796-808. (Pubitemid 38063703)
55. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Investig. 2003;112:1821-30. (Pubitemid 38063705)
56. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes. 2006;55:1554-61. (Pubitemid 44324107)
57. Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008;114:183-94. (Pubitemid 352009305)
58. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999;107:119-25.
59. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14:137-45. (Pubitemid 36733912)
60. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54:2939-45. (Pubitemid 41401090)
61. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Antitumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83-6.
62. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 1996;45:881-5. (Pubitemid 26225502)
63. Seriolo BC, Ferrone, Cutolo M. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol. 2008;35(2):355-7.
64. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:1495-8. (Pubitemid 47201685)
65. Ferraz-Amaro I, Arce-Franco M, Muñiz J, López- Fernández J, Hernández-Hernández V, Franco A, Quevedo J, Martínez- Martín J, Díaz-González F. Systemic blockade of TNF-alpha does not improve insulin resistance in humans. Horm Metab Res. 2011;43:801-8.
66. Schreyer SA, Chua SC Jr, LeBoeuf RC. Obesity and diabetes in TNF-alpha receptor-deficient mice. J Clin Investig. 1998;102: 402-11. (Pubitemid 28335200)
67. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology. 1998;139: 4832-8. (Pubitemid 28533428)
68. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1-78. (Pubitemid 23289250)
69. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196-200. (Pubitemid 27525539)
70. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm. 2009;80:613-33.
71. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75-9.
72. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of agerelated obesity. Am J Physiol Endocrinol Metab. 2004;287: E182-7. (Pubitemid 38856299)
73. Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M, Teshigawara K, Matsuki Y, Watanabe E, Hiramatsu R, Notohara K, Katayose K, Okamura H, Kahn CR, Noda T, Takeda K, Akira S, Inui A, Kasuga M. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006;3:267-75.
74. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology. 2005;146:3417-27. (Pubitemid 41058114)
75. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003;52:2784-9. (Pubitemid 37339708)
76. Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia. 2004;47:1135-42. (Pubitemid 39093309)
77. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55:2688-97. (Pubitemid 44923666)
78. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun. 2003;311: 372-9. (Pubitemid 37340087)
79. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278:45777-84. (Pubitemid 37432722)
80. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301:1045-50. (Pubitemid 36279218)
81. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20:182-9.
82. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56:1010-3. (Pubitemid 46525079)
83. Frolich M, Imhof A, Berg G, Hutchinson W, Pepys M, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population based study. Diabetes Care. 2000;23:1835-9.
84. Majello B, Arcone R, Toniatti C, Ciliberto G. Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter. EMBO J. 1990;9:457-65.
85. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131-5.
86. Faber DR, van der Graaf Y, Westerink J, Visseren FL. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. Atherosclerosis. 2010;212:274-80.
87. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome. Diabetologia. 1997;40:1286-92. (Pubitemid 27469668)
88. Faber DR, van der Graaf Y, Westerink J, Visseren FL. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med. 2004;117:398-405.
89. Howard BV, Best L, Comuzzie A, Ebbesson SO, Epstein SE, Fabsitz RR, Howard WJ, Silverman A, Wang H, Zhu J, Umans J. C-reactive protein, insulin resistance, and metabolic syndrome in a population with a high burden of subclinical infection: insights from the genetics of coronary artery disease in Alaska natives (GOCADAN) study. Diabetes Care. 2008;31:2312-4.
90. Tsuriya D, Morita H, Morioka T, Takahashi N, Ito T, Oki Y, Nakamura H. Significant correlation between visceral adiposity and high-sensitivity C-reactive protein (hs-CRP) in Japanese subjects. Intern Med. 2011;50:2767-73.
91. Xi L, Xiao C, Bandsma RH, Naples M, Adeli K, Lewis GF. C-reactive protein impairs hepatic insulin sensitivity and insulin signaling in rats: role of mitogen-activated protein kinases. Hepatology. 2011;53:127-35.
92. Chieko Mineo, Longoria C, Vongpatanasin W, Shaul PW Abstract 5550: C-reactive protein (CRP) causes insulin resistance in mice through FcRIIB-mediated inhibition of insulin signaling circulation. 2009; 120: S1114.
93. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia. 2002;45:805-12.
94. Holdstock C, Lind L, Engstrom BE, Ohrvall M, Sundbom M, Larsson A, et al. CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. Int J Obes (Lond). 2005;29:1275-80. (Pubitemid 43080308)
95. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4649-54. (Pubitemid 37357506)
96. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003;42:1757-63. (Pubitemid 37433654)
97. van Dielen FM, van't Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord. 2001;25: 1759-66. (Pubitemid 33131915)
98. Chen K, Li F, Li J, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M, Skibinski GA, McCrory MA, Szalai AJ, Zhao AZ. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006;12: 425-32.
99. Finck BN, Johnson RW. Tumor necrosis factor (TNF)-alpha induces leptin production through the p55 TNF receptor. Am J Physiol Regul Integr Comp Physiol. 2000;278:R537-43. (Pubitemid 30129647)
100. Zhao T, Hou M, Xia M, Wang Q, Zhu H, Xiao Y, Tang Z, Ma J, Ling W. Globular adiponectin decreases leptin-induced tumor necrosis factor-alpha expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol. 2005;238:19-30. (Pubitemid 43288029)
101. Tang CH, Lu DY, Yang RS, Tsai HY, Kao MC, Fu WM, Chen YF. Leptin-induced IL-6 production is mediated by leptin receptor, insulin receptor substrate-1, phosphatidylinositol 3-kinase, Akt, NF-kappaB, and p300 pathway in microglia. J Immunol. 2007;179:1292-302.
102. Park PH, McMullen MR, Huang H, Thakur V, Nagy LE. Shortterm treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production. J Biol Chem. 2007;282:21695-703. (Pubitemid 47195777)
103. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107: 671-4. (Pubitemid 36222590)
104. Olszanecka-Glinianowicz M, Kocełak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B. Plasma visfatin and tumor necrosis factor-alpha (TNF-alpha) levels in metabolic syndrome. Kardiol Pol. 2011;69:802-7.
105. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-30. (Pubitemid 40139988)
106. Li H, Liu P, Cepeda J, Fang D, Easley RB, Simon BA, Zhang LQ, Ye SQ. Augmentation of pulmonary epithelial cell IL-8 expression and permeability by pre-B-cell colony enhancing factor. J Inflamm (Lond). 2008;5:15.
107. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748-58. (Pubitemid 46154646)
108. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2005;289:E586-90. (Pubitemid 41356079)
109. Bastard JP, Jardel C, Bruckert E, Vidal H, Hainque B. Variations in plasma soluble tumour necrosis factor receptors after diet-induced weight loss in obesity. Diabetes Obes Metab. 2000; 2:323-5. (Pubitemid 33072202)
110. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol. 2001;21:968-70. (Pubitemid 34168654)
111. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564-9. (Pubitemid 34123429)
112. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000;85:3338-42.
113. Tsukui S, Kanda T, Nara M, Nishino M, Kondo T, Kobayashi I. Moderate intensity regular exercise decreases serum tumor necrosis factor-a and HbA1c levels in healthy women. Int J Obes Relat Metab Disord. 2000;24:1207-11.
114. Straczkowski M, Kowalska I, Dzienis-Straczkowska S, Stepién A, Skibińska E, Szelachowska M, et al. Changes in tumor necrosis factor-a system and insulin sensitivity during an exercise training program in obese women with normal and impaired glucose tolerance. Eur J Endocrinol. 2001;145:273-80. (Pubitemid 32825659)
115. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2006;54:2277-86. (Pubitemid 41134253)
116. Zhang H, Wang Y, Zhang J, Potter BJ, Sowers JR, Zhang C. Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol. 2011;31:2063-9.
117. Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, Granzotto M, Vettor R, Camastra S, Ferrannini E. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes. 2002;51:144-51. (Pubitemid 34517991)
118. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105-12. (Pubitemid 36044411)
119. Bellia A, Garcovich C, D'Adamo M, Lombardo M, Tesauro M, Donadel G et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med. 2011 Epub.